BNP Paribas Financial Markets
IMRX icon

BNP Paribas Financial Markets’s Immuneering IMRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.9K Buy
19,420
+17,144
+753% +$86.7K ﹤0.01% 4571
2026
Q1 		$12K Buy
2,276
+36
+2% +$185 ﹤0.01% 5185
2025
Q4 		$14.7K Buy
2,240
+1,978
+755% +$12.7K ﹤0.01% 5085
2025
Q3 		$1.83K Sell
262
-25
-9% -$130 ﹤0.01% 5178
2025
Q2 		$967 Hold
287
– – ﹤0.01% 5149
2025
Q1 		$436 Sell
287
-62
-18% -$113 ﹤0.01% 5151
2024
Q4 		$768 Buy
+349
New +$724 ﹤0.01% 5115

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

BNP Paribas Financial Markets's IMRX Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Immuneering (IMRX) stake by 753% in Q2 2026, buying an estimated $86.7K and bringing the position to 19,420 shares worth $96.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4571.

BNP Paribas Financial Markets first reported a position in IMRX in Q4 2024 and has held it in 7 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • BNP Paribas Financial Markets held 19,420 shares of Immuneering worth $96.9K as of Q2 2026.
  • BNP Paribas Financial Markets bought 17,144 Immuneering shares in Q2 2026, an estimated $86.7K.
  • Immuneering made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4571 holding.
  • BNP Paribas Financial Markets first reported a position in Immuneering in Q4 2024 and has held it in 7 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.